KaloBios Pharmaceuticals Inc :
* KaloBios reveals initial patient dosed in set 1 study of
Lenzilumab when it come to the procedure of chronic myelomonocytic leukemia
Resource message when it come to Eikon:
Additional firm coverage:
(Bengaluru Newsroom: +1-646-223-8780)
